Label-Free Quantitative Proteomics Analysis of the Sorafenib Resistance in HepG2 Cells

Drug resistance of sorafenib seriously affects the treatment effect of late-stage hepatocellular carcinoma (HCC) patients. However, the precise mechanism of resistance to sorafenib remains unclear. Therefore, to obtain a deep understand of sorafenib resistance mechanisms and find potential therapeut...

Full description

Saved in:
Bibliographic Details
Published inJournal of analysis and testing Vol. 6; no. 3; pp. 308 - 317
Main Authors Wang, Zi-Xuan, Chu, Hong-Wei, Yang, Kai-Guang, Zhao, Bao-Feng, Liang, Zhen, Zhang, Li-Hua, Zhang, Yu-Kui
Format Journal Article
LanguageEnglish
Published Singapore Springer Nature Singapore 01.09.2022
Subjects
Analytical Chemistry
Characterization and Evaluation of Materials
Chemistry
Chemistry and Materials Science
Monitoring/Environmental Analysis
Original Paper
Hepatocellular carcinoma
Quantitative proteomics
Drug resistance
Sorafenib
Online AccessGet full text

Cover

Abstract Drug resistance of sorafenib seriously affects the treatment effect of late-stage hepatocellular carcinoma (HCC) patients. However, the precise mechanism of resistance to sorafenib remains unclear. Therefore, to obtain a deep understand of sorafenib resistance mechanisms and find potential therapeutic targets are very important for improving the clinical prognosis of HCC patients. In this study, a label-free quantitative proteomics method was performed to investigate the proteins differentially expressed between HepG2 and the sorafenib-acquired resistance HepG2 (HepG2-R) cells. In total, 84 differential expressed proteins were identified between the two cell lines. Bioinformatics analysis results demonstrated the dysregulated metabolic processes have a significant impact on the drug resistance of HepG2-R cells. Among them, the expression of Microsomal glutathione S-transferase 1 (MGST1) in two cell lines was further confirmed by western blot method. Moreover, colony formation assay and trypan blue dye assay results revealed that MGST1 is closely connected with the sorafenib resistance of HepG2-R cells, and the knockdown of MGST1 increased the sensitivity of sorafenib resistance HepG2-R cells to sorafenib treatment. In conclusion, these results lay a foundation for deciphering the mechanism for HCC sorafenib resistance and present a possibility of MGST1 serving as a therapeutic target for the treatment of sorafenib resistance HCC.
AbstractList Drug resistance of sorafenib seriously affects the treatment effect of late-stage hepatocellular carcinoma (HCC) patients. However, the precise mechanism of resistance to sorafenib remains unclear. Therefore, to obtain a deep understand of sorafenib resistance mechanisms and find potential therapeutic targets are very important for improving the clinical prognosis of HCC patients. In this study, a label-free quantitative proteomics method was performed to investigate the proteins differentially expressed between HepG2 and the sorafenib-acquired resistance HepG2 (HepG2-R) cells. In total, 84 differential expressed proteins were identified between the two cell lines. Bioinformatics analysis results demonstrated the dysregulated metabolic processes have a significant impact on the drug resistance of HepG2-R cells. Among them, the expression of Microsomal glutathione S-transferase 1 (MGST1) in two cell lines was further confirmed by western blot method. Moreover, colony formation assay and trypan blue dye assay results revealed that MGST1 is closely connected with the sorafenib resistance of HepG2-R cells, and the knockdown of MGST1 increased the sensitivity of sorafenib resistance HepG2-R cells to sorafenib treatment. In conclusion, these results lay a foundation for deciphering the mechanism for HCC sorafenib resistance and present a possibility of MGST1 serving as a therapeutic target for the treatment of sorafenib resistance HCC.
Author Liang, Zhen
Wang, Zi-Xuan
Chu, Hong-Wei
Zhang, Yu-Kui
Yang, Kai-Guang
Zhang, Li-Hua
Zhao, Bao-Feng
Author_xml – sequence: 1
  givenname: Zi-Xuan
  surname: Wang
  fullname: Wang, Zi-Xuan
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science, University of Chinese Academy of Sciences
– sequence: 2
  givenname: Hong-Wei
  surname: Chu
  fullname: Chu, Hong-Wei
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science, Zhang Dayu School of Chemistry, Dalian University of Technology
– sequence: 3
  givenname: Kai-Guang
  surname: Yang
  fullname: Yang, Kai-Guang
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science
– sequence: 4
  givenname: Bao-Feng
  surname: Zhao
  fullname: Zhao, Bao-Feng
  email: baofzhao@dicp.ac.cn
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science
– sequence: 5
  givenname: Zhen
  surname: Liang
  fullname: Liang, Zhen
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science
– sequence: 6
  givenname: Li-Hua
  surname: Zhang
  fullname: Zhang, Li-Hua
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science
– sequence: 7
  givenname: Yu-Kui
  surname: Zhang
  fullname: Zhang, Yu-Kui
  organization: CAS Key Laboratory of Separation Science for Analytical Chemistry, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Science, Zhang Dayu School of Chemistry, Dalian University of Technology
BookMark eNp9kNtKAzEQhoNUUGtfwKu8QDSnTTaXpdhWKHgW70I2nWhkzZZkK-3bu1qvvZphmO-H_ztDo9QlQOiC0UtGqb4qkiklCeWMUMq0IrsjdMoraohURo2GnRpFuGSvJ2hSSmyorAWXtVKn6GXlGmjJPAPg-61LfexdH78A3-Wuh-4z-oKnybX7EgvuAu7fAT922QVIscEPMJx7lzzgmPASNguOZ9C25RwdB9cWmPzNMXqeXz_NlmR1u7iZTVfEc8N60gTtGK2EMcFTH5xk2ph1kEE3QkMFXCqvvdK1FrVYV96z0IQ1q0A0ktUexBjxQ67PXSkZgt3k-Ony3jJqf-TYgxw7yLG_cuxugMQBKsNzeoNsP7ptHkqW_6hvnFdqxg
CitedBy_id crossref_primary_10_1016_j_fmre_2024_04_015
Cites_doi 10.1038/sj.onc.1209373
10.1038/s41575-019-0186-y
10.1002/ijc.27604
10.3310/hta14Suppl1/03
10.1021/mp2000692
10.7150/jca.31448
10.1002/prca.201900080
10.3892/or.2018.6606
10.1016/j.canlet.2018.04.013
10.1074/jbc.275.17.13000
10.1038/nmeth.3901
10.21873/cgp.20080
10.1074/mcp.M114.046417
10.4161/cbt.8.20.9436
10.1074/mcp.TIR119.001827
10.3390/cancers12082116
10.7150/thno.25487
10.4254/wjh.v6.i10.752
10.1074/jbc.M009400200
10.1016/j.bbrc.2007.02.018
10.1016/j.canlet.2019.02.040
10.3389/fphar.2012.00005
10.3892/ol.2013.1768
10.1016/j.ejphar.2019.172883
10.3350/cmh.2019.0031
10.3892/ol.2015.3315
10.1093/carcin/bgab019
10.1002/cncr.28730
10.1016/0006-2952(84)90145-x
10.1158/0008-5472.Can-04-1443
ContentType Journal Article
Copyright The Nonferrous Metals Society of China 2021
Copyright_xml – notice: The Nonferrous Metals Society of China 2021
DBID AAYXX
CITATION
DOI 10.1007/s41664-021-00176-x
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 2509-4696
EndPage 317
ExternalDocumentID 10_1007_s41664_021_00176_x
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 21834006; 32071434
  funderid: http://dx.doi.org/10.13039/501100001809
– fundername: National Key Research and Development Program of China
  grantid: 2016YFA0501401
GroupedDBID -EM
406
AAFGU
AAHNG
AAIAL
AANZL
AARHV
AATNV
AATVU
AAUYE
AAXDM
AAYFA
ABDZT
ABECU
ABFGW
ABFTV
ABJNI
ABJOX
ABKAS
ABKCH
ABMQK
ABQBU
ABTEG
ABTKH
ABTMW
ABXPI
ACBMV
ACBRV
ACBYP
ACGFS
ACHSB
ACIGE
ACIPQ
ACMLO
ACOKC
ACTTH
ACVWB
ACWMK
ADHHG
ADKNI
ADKPE
ADMDM
ADOXG
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFTE
AEJRE
AEOHA
AESKC
AESTI
AEVLU
AEVTX
AEXYK
AFNRJ
AFQWF
AGDGC
AGGBP
AGJBK
AGMZJ
AHKAY
AHSBF
AIAKS
AILAN
AIMYW
AITGF
AJDOV
AJRNO
AJZVZ
AKQUC
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
AXYYD
BGNMA
CSCUP
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
FERAY
FINBP
FNLPD
FSGXE
GGCAI
GJIRD
IKXTQ
IWAJR
J-C
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O9J
PT4
RLLFE
RSV
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
TSG
UOJIU
UTJUX
UZXMN
VFIZW
Z7X
ZMTXR
-SB
-S~
0R~
AACDK
AAJBT
AASML
AAYXX
ABAKF
ACAOD
ACDTI
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
CAJEB
CITATION
FIGPU
H13
HG6
Q--
ROL
SJYHP
U1G
U5L
ID FETCH-LOGICAL-c291t-bf7a105399fc0cfa41799df4f7b37e5e246c7c6787383d5cc1fbfd15e3b418ce3
ISSN 2096-241X
IngestDate Thu Sep 12 17:56:18 EDT 2024
Sat Dec 16 12:08:26 EST 2023
IsPeerReviewed false
IsScholarly true
Issue 3
Keywords Hepatocellular carcinoma
Quantitative proteomics
Drug resistance
Sorafenib
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c291t-bf7a105399fc0cfa41799df4f7b37e5e246c7c6787383d5cc1fbfd15e3b418ce3
PageCount 10
ParticipantIDs crossref_primary_10_1007_s41664_021_00176_x
springer_journals_10_1007_s41664_021_00176_x
PublicationCentury 2000
PublicationDate 2022-09-01
PublicationDateYYYYMMDD 2022-09-01
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-01
  day: 01
PublicationDecade 2020
PublicationPlace Singapore
PublicationPlace_xml – name: Singapore
PublicationTitle Journal of analysis and testing
PublicationTitleAbbrev J. Anal. Test
PublicationYear 2022
Publisher Springer Nature Singapore
Publisher_xml – name: Springer Nature Singapore
References Ezzoukhry, Louandre, Trecherel, Godin, Chauffert, Dupont, Diouf, Barbare, Maziere, Galmiche (CR5) 2012; 131
Liu, Dong, Lv, Xiu, Li, Wang, Xu, Li (CR7) 2015; 10
Takimoto-Shimomura, Nagoshi, Maegawa, Fujibayashi, Tsukamoto, Matsumura-Kimoto, Mizuno, Chinen, Mizutani, Shimura, Horiike, Taniwaki, Kobayashi, Kuroda (CR27) 2018; 15
Connock, Round, Bayliss, Tubeuf, Greenheld, Moore (CR30) 2010; 14
Chiou, Tai, Wang, Liu, Jen, Shiau (CR31) 2009; 8
Shirato, Kikugawa, Miura, Tanji, Takemori, Higashiyama, Yokoyama (CR23) 2014; 7
Yang, Hainaut, Gores, Amadou, Plymoth, Roberts (CR1) 2019; 16
Yeh, Hsu, Shao, Ho, Tsai, Feng, Chow (CR11) 2015; 14
Wilhelm, Carter, Tang, Wilkie, McNabola, Rong, Chen, Zhang, Vincent, McHugh, Cao, Shujath, Gawlak, Eveleigh, Rowley, Liu, Adnane, Lynch, Auclair, Taylor, Gedrich, Voznesensky, Riedl, Post, Bollag, Trail (CR3) 2004; 64
Fischer, Wang, Vlada, Kim, Behrns (CR6) 2014; 6
Paumi, Ledford, Smitherman, Townsend, Morrow (CR21) 2001; 276
Kelner, Bagnell, Montoya, Estes, Forsberg, Morgenstern (CR25) 2000; 275
Luo, Wu, Zhang, Shu, Ding, Chen, Zhao, Chang, Zhu, Liu (CR19) 2018; 427
Valinezhad Sani, Palizban, Mosaffa, Jamialahmadi (CR18) 2020; 868
Hu, Cheng, Hu, Li, Ma, Tang, Sun, Guo, Huang, Zhou, Gao, Cao, Qiu, Zhou, Fan, Yang (CR8) 2019; 10
Fan, Duan, Wang, Xiao, Li, Yan, Yao, Wu, Zhang, Zhang, Li, Zhu, Hu, Zhang, Jiao, Xu (CR10) 2019; 450
Liu, Fan, Li, Cheng, Lin, Li, Du, Ling (CR16) 2018; 40
Sun, Dong, Li, Chu, Liu, Hao, Zhang, Zhao, Wang, Zhang (CR12) 2020; 5
Morgenstern, Lundqvist, Andersson, Balk, DePierre (CR26) 1984; 33
Fang, Zhao, Chu, Liu, Zhao, Liang, Zhang, Li, Wang, Qin, Zhang (CR13) 2020; 19
Inoue, Tomisawa, Yamazaki, Abe, Suemizu, Tsukamoto, Tomii, Kawamura, Kijima, Hatanaka, Ueyama, Nakamura, Kobayashi (CR24) 2003; 23
Marin, Perez-Silva, Macias, Asensio, Peleteiro-Vigil, Sanchez-Martin, Cives-Losada, Sanchon-Sanchez, De Blas, Herraez, Briz, Lozano (CR29) 2020; 12
Matsunaga, Wada, Endo, Soda, El-Kabbani, Hara (CR22) 2012; 3
Fong, Tanabe (CR2) 2014; 120
Johansson, Ito, Schophuizen, Mathew Thengumtharayil, Heuser, Zhang, Shimoji, Vahter, Ang, Dyson, Shibata, Shuto, Ito, Abe, Morgenstern (CR28) 2011; 8
Tyanova, Temu, Sinitcyn, Carlson, Hein, Geiger, Mann, Cox (CR14) 2016; 13
Siritantikorn, Johansson, Ahlen, Rinaldi, Suthiphongchai, Wilairat, Morgenstern (CR32) 2007; 355
McIlwain, Townsend, Tew (CR20) 2006; 25
Wu, Wang, Chok, Man, Tsang, Chan, Ma, Xia, Cheung (CR9) 2018; 8
Makol, Kaur, Sharma, Kanthaje, Kaur, Chakraborti (CR15) 2020; 26
Chu, Changqing Wu, Sun, Yang, Zhao, Yang, Liang, Zhong, Zhang, Zhang (CR17) 2021
Llovet, Ricci, Mazzaferro, Hilgard, Gane, Blanc, de Oliveira, Santoro, Raoul, Forner, Schwartz, Porta, Zeuzem, Bolondi, Greten, Galle, Seitz, Borbath, Haussinger, Giannaris, Shan, Moscovici, Voliotis, Bruix (CR4) 2008; 359
JD Yang (176_CR1) 2019; 16
H Chu (176_CR17) 2021
S Tyanova (176_CR14) 2016; 13
MJ Kelner (176_CR25) 2000; 275
A Makol (176_CR15) 2020; 26
JJG Marin (176_CR29) 2020; 12
A Shirato (176_CR23) 2014; 7
ZV Fong (176_CR2) 2014; 120
TD Fischer (176_CR6) 2014; 6
CC McIlwain (176_CR20) 2006; 25
F Liu (176_CR7) 2015; 10
A Siritantikorn (176_CR32) 2007; 355
R Sun (176_CR12) 2020; 5
F Fang (176_CR13) 2020; 19
Y Inoue (176_CR24) 2003; 23
Q Luo (176_CR19) 2018; 427
CX Wu (176_CR9) 2018; 8
T Takimoto-Shimomura (176_CR27) 2018; 15
K Johansson (176_CR28) 2011; 8
SM Wilhelm (176_CR3) 2004; 64
JF Chiou (176_CR31) 2009; 8
CM Paumi (176_CR21) 2001; 276
JM Llovet (176_CR4) 2008; 359
Z Ezzoukhry (176_CR5) 2012; 131
Z Fan (176_CR10) 2019; 450
R Morgenstern (176_CR26) 1984; 33
CC Yeh (176_CR11) 2015; 14
F Valinezhad Sani (176_CR18) 2020; 868
M Connock (176_CR30) 2010; 14
T Matsunaga (176_CR22) 2012; 3
B Hu (176_CR8) 2019; 10
D Liu (176_CR16) 2018; 40
References_xml – volume: 25
  start-page: 1639
  issue: 11
  year: 2006
  end-page: 1648
  ident: CR20
  article-title: Glutathione S-transferase polymorphisms: cancer incidence and therapy
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209373
  contributor:
    fullname: Tew
– volume: 16
  start-page: 589
  issue: 10
  year: 2019
  end-page: 604
  ident: CR1
  article-title: A global view of hepatocellular carcinoma: trends, risk, prevention and management
  publication-title: Nat Rev Gastro Hepat
  doi: 10.1038/s41575-019-0186-y
  contributor:
    fullname: Roberts
– volume: 131
  start-page: 2961
  issue: 12
  year: 2012
  end-page: 2969
  ident: CR5
  article-title: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27604
  contributor:
    fullname: Galmiche
– volume: 14
  start-page: 17
  issue: Suppl 1
  year: 2010
  end-page: 21
  ident: CR30
  article-title: Sorafenib for the treatment of advanced hepatocellular carcinoma
  publication-title: Health Technol Assess
  doi: 10.3310/hta14Suppl1/03
  contributor:
    fullname: Moore
– volume: 8
  start-page: 1698
  issue: 5
  year: 2011
  end-page: 1708
  ident: CR28
  article-title: Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance
  publication-title: Mol Pharm
  doi: 10.1021/mp2000692
  contributor:
    fullname: Morgenstern
– volume: 10
  start-page: 3914
  issue: 17
  year: 2019
  end-page: 3925
  ident: CR8
  article-title: KPNA3 confers sorafenib resistance to advanced hepatocellular carcinoma via TWIST regulated Epithelial-Mesenchymal transition
  publication-title: J Cancer
  doi: 10.7150/jca.31448
  contributor:
    fullname: Yang
– volume: 5
  start-page: 14
  year: 2020
  ident: CR12
  article-title: Proteomic analysis reveals that EPHX1 contributes to 5-fluorouracil resistance in a human hepatocellular carcinoma cell line
  publication-title: Proteom Clin Appl.
  doi: 10.1002/prca.201900080
  contributor:
    fullname: Zhang
– volume: 40
  start-page: 2206
  issue: 4
  year: 2018
  end-page: 2214
  ident: CR16
  article-title: Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stressrelated autophagy in hepatocellular carcinoma
  publication-title: Oncol Rep
  doi: 10.3892/or.2018.6606
  contributor:
    fullname: Ling
– volume: 427
  start-page: 9
  year: 2018
  end-page: 17
  ident: CR19
  article-title: ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2018.04.013
  contributor:
    fullname: Liu
– volume: 275
  start-page: 13000
  issue: 17
  year: 2000
  end-page: 13006
  ident: CR25
  article-title: Structural organization of the microsomal glutathione S-transferase gene (MGST1) on chromosome 12p13.1–13.2. Identification of the correct promoter region and demonstration of transcriptional regulation in response to oxidative stress
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.275.17.13000
  contributor:
    fullname: Morgenstern
– volume: 13
  start-page: 731
  issue: 9
  year: 2016
  end-page: 740
  ident: CR14
  article-title: The Perseus computational platform for comprehensive analysis of (prote)omics data
  publication-title: Nat Methods
  doi: 10.1038/nmeth.3901
  contributor:
    fullname: Cox
– volume: 15
  start-page: 213
  issue: 3
  year: 2018
  end-page: 223
  ident: CR27
  article-title: Establishment and characteristics of a novel mantle cell lymphoma-derived cell line and a bendamustine-resistant subline
  publication-title: Cancer Genom Proteom
  doi: 10.21873/cgp.20080
  contributor:
    fullname: Kuroda
– volume: 14
  start-page: 1527
  issue: 6
  year: 2015
  end-page: 1545
  ident: CR11
  article-title: Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies Galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
  publication-title: Mol Cell Proteom
  doi: 10.1074/mcp.M114.046417
  contributor:
    fullname: Chow
– volume: 8
  start-page: 1904
  issue: 20
  year: 2009
  end-page: 1913
  ident: CR31
  article-title: Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.8.20.9436
  contributor:
    fullname: Shiau
– volume: 19
  start-page: 1724
  issue: 10
  year: 2020
  end-page: 1737
  ident: CR13
  article-title: Molecular dynamics simulation-assisted ionic liquid screening for deep coverage proteome analysis
  publication-title: Mol Cell Proteom
  doi: 10.1074/mcp.TIR119.001827
  contributor:
    fullname: Zhang
– volume: 12
  start-page: 2116
  issue: 8
  year: 2020
  ident: CR29
  article-title: Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma
  publication-title: Cancers
  doi: 10.3390/cancers12082116
  contributor:
    fullname: Lozano
– volume: 359
  start-page: 2508
  issue: 23
  year: 2008
  end-page: 2508
  ident: CR4
  article-title: Sorafenib in advanced hepatocellular carcinoma
  publication-title: New Engl J Med
  contributor:
    fullname: Bruix
– volume: 8
  start-page: 3737
  issue: 14
  year: 2018
  end-page: 3750
  ident: CR9
  article-title: Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma
  publication-title: Theranostics
  doi: 10.7150/thno.25487
  contributor:
    fullname: Cheung
– volume: 6
  start-page: 752
  issue: 10
  year: 2014
  end-page: 758
  ident: CR6
  article-title: Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib
  publication-title: World J Hepatol
  doi: 10.4254/wjh.v6.i10.752
  contributor:
    fullname: Behrns
– volume: 276
  start-page: 7952
  issue: 11
  year: 2001
  end-page: 7956
  ident: CR21
  article-title: Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1–1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M009400200
  contributor:
    fullname: Morrow
– volume: 355
  start-page: 592
  issue: 2
  year: 2007
  end-page: 596
  ident: CR32
  article-title: Protection of cells from oxidative stress by microsomal glutathione transferase 1
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2007.02.018
  contributor:
    fullname: Morgenstern
– volume: 450
  start-page: 132
  year: 2019
  end-page: 143
  ident: CR10
  article-title: PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/beta-catenin signaling
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.02.040
  contributor:
    fullname: Xu
– volume: 3
  start-page: 5
  year: 2012
  ident: CR22
  article-title: Aldo-Keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2012.00005
  contributor:
    fullname: Hara
– volume: 7
  start-page: 674
  issue: 3
  year: 2014
  end-page: 678
  ident: CR23
  article-title: Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells
  publication-title: Oncol Lett
  doi: 10.3892/ol.2013.1768
  contributor:
    fullname: Yokoyama
– volume: 23
  start-page: 1333
  issue: 5
  year: 2003
  end-page: 1339
  ident: CR24
  article-title: The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer
  publication-title: Int J Oncol
  contributor:
    fullname: Kobayashi
– volume: 868
  start-page: 172883
  year: 2020
  ident: CR18
  article-title: Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2019.172883
  contributor:
    fullname: Jamialahmadi
– volume: 26
  start-page: 45
  issue: 1
  year: 2020
  end-page: 53
  ident: CR15
  article-title: Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
  publication-title: Clin Mol Hepatol
  doi: 10.3350/cmh.2019.0031
  contributor:
    fullname: Chakraborti
– volume: 10
  start-page: 778
  issue: 2
  year: 2015
  end-page: 784
  ident: CR7
  article-title: Targeting hypoxia-inducible factor-2 alpha enhances sorafenib antitumor activity via beta-catenin/C-Myc-dependent pathways in hepatocellular carcinoma
  publication-title: Oncol Lett
  doi: 10.3892/ol.2015.3315
  contributor:
    fullname: Li
– year: 2021
  ident: CR17
  article-title: Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgab019
  contributor:
    fullname: Zhang
– volume: 120
  start-page: 2824
  issue: 18
  year: 2014
  end-page: 2838
  ident: CR2
  article-title: The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia a comprehensive and evidence-based comparison and review
  publication-title: Cancer
  doi: 10.1002/cncr.28730
  contributor:
    fullname: Tanabe
– volume: 33
  start-page: 3609
  issue: 22
  year: 1984
  end-page: 3614
  ident: CR26
  article-title: The distribution of microsomal glutathione transferase among different organelles, different organs, and different organisms
  publication-title: Biochem Pharmacol
  doi: 10.1016/0006-2952(84)90145-x
  contributor:
    fullname: DePierre
– volume: 64
  start-page: 7099
  issue: 19
  year: 2004
  end-page: 7109
  ident: CR3
  article-title: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
  publication-title: Can Res
  doi: 10.1158/0008-5472.Can-04-1443
  contributor:
    fullname: Trail
– year: 2021
  ident: 176_CR17
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgab019
  contributor:
    fullname: H Chu
– volume: 868
  start-page: 172883
  year: 2020
  ident: 176_CR18
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2019.172883
  contributor:
    fullname: F Valinezhad Sani
– volume: 8
  start-page: 3737
  issue: 14
  year: 2018
  ident: 176_CR9
  publication-title: Theranostics
  doi: 10.7150/thno.25487
  contributor:
    fullname: CX Wu
– volume: 15
  start-page: 213
  issue: 3
  year: 2018
  ident: 176_CR27
  publication-title: Cancer Genom Proteom
  doi: 10.21873/cgp.20080
  contributor:
    fullname: T Takimoto-Shimomura
– volume: 276
  start-page: 7952
  issue: 11
  year: 2001
  ident: 176_CR21
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M009400200
  contributor:
    fullname: CM Paumi
– volume: 5
  start-page: 14
  year: 2020
  ident: 176_CR12
  publication-title: Proteom Clin Appl.
  doi: 10.1002/prca.201900080
  contributor:
    fullname: R Sun
– volume: 23
  start-page: 1333
  issue: 5
  year: 2003
  ident: 176_CR24
  publication-title: Int J Oncol
  contributor:
    fullname: Y Inoue
– volume: 14
  start-page: 17
  issue: Suppl 1
  year: 2010
  ident: 176_CR30
  publication-title: Health Technol Assess
  doi: 10.3310/hta14Suppl1/03
  contributor:
    fullname: M Connock
– volume: 19
  start-page: 1724
  issue: 10
  year: 2020
  ident: 176_CR13
  publication-title: Mol Cell Proteom
  doi: 10.1074/mcp.TIR119.001827
  contributor:
    fullname: F Fang
– volume: 355
  start-page: 592
  issue: 2
  year: 2007
  ident: 176_CR32
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2007.02.018
  contributor:
    fullname: A Siritantikorn
– volume: 16
  start-page: 589
  issue: 10
  year: 2019
  ident: 176_CR1
  publication-title: Nat Rev Gastro Hepat
  doi: 10.1038/s41575-019-0186-y
  contributor:
    fullname: JD Yang
– volume: 8
  start-page: 1698
  issue: 5
  year: 2011
  ident: 176_CR28
  publication-title: Mol Pharm
  doi: 10.1021/mp2000692
  contributor:
    fullname: K Johansson
– volume: 7
  start-page: 674
  issue: 3
  year: 2014
  ident: 176_CR23
  publication-title: Oncol Lett
  doi: 10.3892/ol.2013.1768
  contributor:
    fullname: A Shirato
– volume: 64
  start-page: 7099
  issue: 19
  year: 2004
  ident: 176_CR3
  publication-title: Can Res
  doi: 10.1158/0008-5472.Can-04-1443
  contributor:
    fullname: SM Wilhelm
– volume: 120
  start-page: 2824
  issue: 18
  year: 2014
  ident: 176_CR2
  publication-title: Cancer
  doi: 10.1002/cncr.28730
  contributor:
    fullname: ZV Fong
– volume: 13
  start-page: 731
  issue: 9
  year: 2016
  ident: 176_CR14
  publication-title: Nat Methods
  doi: 10.1038/nmeth.3901
  contributor:
    fullname: S Tyanova
– volume: 26
  start-page: 45
  issue: 1
  year: 2020
  ident: 176_CR15
  publication-title: Clin Mol Hepatol
  doi: 10.3350/cmh.2019.0031
  contributor:
    fullname: A Makol
– volume: 359
  start-page: 2508
  issue: 23
  year: 2008
  ident: 176_CR4
  publication-title: New Engl J Med
  contributor:
    fullname: JM Llovet
– volume: 40
  start-page: 2206
  issue: 4
  year: 2018
  ident: 176_CR16
  publication-title: Oncol Rep
  doi: 10.3892/or.2018.6606
  contributor:
    fullname: D Liu
– volume: 25
  start-page: 1639
  issue: 11
  year: 2006
  ident: 176_CR20
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209373
  contributor:
    fullname: CC McIlwain
– volume: 14
  start-page: 1527
  issue: 6
  year: 2015
  ident: 176_CR11
  publication-title: Mol Cell Proteom
  doi: 10.1074/mcp.M114.046417
  contributor:
    fullname: CC Yeh
– volume: 450
  start-page: 132
  year: 2019
  ident: 176_CR10
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.02.040
  contributor:
    fullname: Z Fan
– volume: 10
  start-page: 3914
  issue: 17
  year: 2019
  ident: 176_CR8
  publication-title: J Cancer
  doi: 10.7150/jca.31448
  contributor:
    fullname: B Hu
– volume: 3
  start-page: 5
  year: 2012
  ident: 176_CR22
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2012.00005
  contributor:
    fullname: T Matsunaga
– volume: 6
  start-page: 752
  issue: 10
  year: 2014
  ident: 176_CR6
  publication-title: World J Hepatol
  doi: 10.4254/wjh.v6.i10.752
  contributor:
    fullname: TD Fischer
– volume: 8
  start-page: 1904
  issue: 20
  year: 2009
  ident: 176_CR31
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.8.20.9436
  contributor:
    fullname: JF Chiou
– volume: 12
  start-page: 2116
  issue: 8
  year: 2020
  ident: 176_CR29
  publication-title: Cancers
  doi: 10.3390/cancers12082116
  contributor:
    fullname: JJG Marin
– volume: 131
  start-page: 2961
  issue: 12
  year: 2012
  ident: 176_CR5
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27604
  contributor:
    fullname: Z Ezzoukhry
– volume: 33
  start-page: 3609
  issue: 22
  year: 1984
  ident: 176_CR26
  publication-title: Biochem Pharmacol
  doi: 10.1016/0006-2952(84)90145-x
  contributor:
    fullname: R Morgenstern
– volume: 10
  start-page: 778
  issue: 2
  year: 2015
  ident: 176_CR7
  publication-title: Oncol Lett
  doi: 10.3892/ol.2015.3315
  contributor:
    fullname: F Liu
– volume: 427
  start-page: 9
  year: 2018
  ident: 176_CR19
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2018.04.013
  contributor:
    fullname: Q Luo
– volume: 275
  start-page: 13000
  issue: 17
  year: 2000
  ident: 176_CR25
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.275.17.13000
  contributor:
    fullname: MJ Kelner
SSID ssib048324866
ssib031263658
ssj0002734730
ssib051367655
Score 2.256235
Snippet Drug resistance of sorafenib seriously affects the treatment effect of late-stage hepatocellular carcinoma (HCC) patients. However, the precise mechanism of...
SourceID crossref
springer
SourceType Aggregation Database
Publisher
StartPage 308
SubjectTerms Analytical Chemistry
Characterization and Evaluation of Materials
Chemistry
Chemistry and Materials Science
Monitoring/Environmental Analysis
Original Paper
Title Label-Free Quantitative Proteomics Analysis of the Sorafenib Resistance in HepG2 Cells
URI https://link.springer.com/article/10.1007/s41664-021-00176-x
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZLcmgvpemDpk2DDr2lKmtLfh2TJZvQRyg0aZdcjCRLictih-wuhP6K_uSOXra3aUrTizFCDEbzeeaTNA-E3vAMnJjQjDAqx4RVMSMiUZxUkqeSclpwe3v-6SQ9PmPvZ8lsNPo5iFpaLcU7-eOPeSX_o1UYA72aLNl7aLYTCgPwDvqFJ2gYnv-k449cqDmZXitlgjMbmy9mIoE-m-ILJt14sVZ0xHDML6ByrZpamIN7wx3Nj23rXV0dxXsTNZ8v7uCrPEiyMZemOId3evY43pmM85rMVj3eJpcr69ra5oJ8U3VnYfzsD7wmANFezPklb90lSEtgoS-GRxKwmw0xV95yxbAvIkANZs7JuLHEtLNLXfvaYHrTAcLowIzScT7wyNRld94y9i6-YwGUMmXEhJoYl5uSm961hev83zxeF4fY1Wy2MkqQUVoZZleyGYPpApu5uT89ODgJNopGcUoH9XIYWESW95Q4sSXwfK7vd18-KLMtb7pV8blbNoPz1sev86P1y3nLeU4fo0de-XjfIW8LjVTzBD2YhB6BT9HXHoF4iEDcIxAHBOJWY0Ag7hCIewTiusEWgdgi8Bk6mx6eTo6J79RBZFxESyJ0xoGoA9nVciw1N23tikoznQmaqUTFLJWZBF6U0ZxWiZSRFrqKEkUFi3Kp6HO00bSNeoGwrGisac7zWFBWqYIrzqVJpxaSU1Uk22gvrE955QqylHercRu9DUtY-h938ZfpL-8l_BV62KN_B20sr1fqNVDUpdj1qPkFf3yIUw
link.rule.ids 315,783,787,27936,27937
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Label-Free+Quantitative+Proteomics+Analysis+of+the+Sorafenib+Resistance+in+HepG2+Cells&rft.jtitle=Journal+of+analysis+and+testing&rft.au=Wang%2C+Zi-Xuan&rft.au=Chu%2C+Hong-Wei&rft.au=Yang%2C+Kai-Guang&rft.au=Zhao%2C+Bao-Feng&rft.date=2022-09-01&rft.issn=2096-241X&rft.eissn=2509-4696&rft.volume=6&rft.issue=3&rft.spage=308&rft.epage=317&rft_id=info:doi/10.1007%2Fs41664-021-00176-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s41664_021_00176_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2096-241X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2096-241X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2096-241X&client=summon